Acrivon Therapeutics (ACRV) Projected to Post Earnings on Thursday

Acrivon Therapeutics (NASDAQ:ACRV) is anticipated to issue its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $0.1660 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Acrivon Therapeutics Stock Down 1.2%

Shares of NASDAQ ACRV opened at $1.64 on Thursday. The firm’s 50-day simple moving average is $1.72 and its 200 day simple moving average is $1.94. The company has a market cap of $51.76 million, a price-to-earnings ratio of -0.77 and a beta of 1.79. Acrivon Therapeutics has a 12-month low of $1.05 and a 12-month high of $5.65.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ACRV shares. Jefferies Financial Group reaffirmed a “buy” rating on shares of Acrivon Therapeutics in a research note on Monday, March 2nd. Piper Sandler increased their price target on shares of Acrivon Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Wall Street Zen lowered shares of Acrivon Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Acrivon Therapeutics in a research report on Monday, December 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $19.00 price objective on shares of Acrivon Therapeutics in a report on Tuesday, November 25th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.67.

Insider Transactions at Acrivon Therapeutics

In other Acrivon Therapeutics news, CEO Peter Blume-Jensen bought 49,000 shares of Acrivon Therapeutics stock in a transaction dated Wednesday, January 14th. The shares were bought at an average price of $1.68 per share, with a total value of $82,320.00. Following the purchase, the chief executive officer owned 2,095,771 shares of the company’s stock, valued at $3,520,895.28. This trade represents a 2.39% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last 90 days, insiders have bought 67,832 shares of company stock worth $114,534. Corporate insiders own 11.90% of the company’s stock.

Hedge Funds Weigh In On Acrivon Therapeutics

Several large investors have recently bought and sold shares of the business. Schonfeld Strategic Advisors LLC acquired a new stake in Acrivon Therapeutics during the 4th quarter worth $40,000. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Acrivon Therapeutics in the 4th quarter valued at $44,000. Focus Partners Wealth acquired a new position in shares of Acrivon Therapeutics in the 3rd quarter valued at $36,000. Quadrature Capital Ltd bought a new position in shares of Acrivon Therapeutics in the 4th quarter worth $50,000. Finally, Invesco Ltd. acquired a new stake in shares of Acrivon Therapeutics during the first quarter worth $72,000. 71.62% of the stock is currently owned by institutional investors and hedge funds.

About Acrivon Therapeutics

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.